Related Experiment Video
Updated: May 17, 2025

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Targeting Gene C9orf72 Pathogenesis for Amyotrophic Lateral Sclerosis
Zhao Zhong Chong1, Nizar Souayah2
1Department of Neurology, New Jersey Medical School, Rutgers University, 185 S Orange, Newark, NJ 07103, USA.
Abstract:
Amyotrophic lateral sclerosis (ALS) is a fatal adult neurodegenerative disorder. Since no cure has been found, finding effective therapeutic targets for ALS remains a major challenge. Gene C9orf72 mutations with the formation of hexanucleotide repeat (GGGGCC) expansion (HRE) have been considered the most common genetic pathogenesis of ALS. The literature review indicates that the C9orf72 HRE causes both the gain-of-function toxicity and loss of function of C9ORF72. The formation of RNA foci and dipeptide repeats (DPRs) resulting from HRE is responsible for toxic function gain. The RNA foci can interfere with RNA processing, while DPRs directly bind to and sequester associated proteins to disrupt processes of rRNA synthesis, mRNA translation, autophagy, and nucleocytoplasmic transport. The mutations of C9orf72 and HRE result in the loss of functional C9ORF72. Under physiological conditions, C9ORF72 binds to Smith-Magenis chromosome region 8 and WD repeat-containing protein and forms a protein complex. Loss of C9ORF72 leads to autophagic impairment, increased oxidative stress, nucleocytoplasmic transport impairment, and inflammatory response. The attempted treatments for ALS have been tried by targeting C9orf72 HRE; however, the outcomes are far from satisfactory yet. More studies should be performed on pharmacological and molecular modulators against C9orf72 HRE to evaluate their efficacy by targeting HRE.
Insights
C9orf72 gene hexanucleotide repeat expansions cause amyotrophic lateral sclerosis (ALS) through toxic gain-of-function and loss-of-function mechanisms. Targeting these expansions is crucial for developing effective ALS therapies.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no cure.
- C9orf72 gene mutations, specifically hexanucleotide repeat expansions (HRE), are the most common genetic cause of ALS.
- Understanding the pathogenic mechanisms of C9orf72 HRE is critical for therapeutic development.
Purpose of the Study:
- To review the literature on the pathogenesis of C9orf72 HRE in ALS.
- To elucidate the dual gain-of-function and loss-of-function mechanisms.
- To discuss current therapeutic strategies and future directions.
Main Methods:
- Literature review of studies on C9orf72 mutations and ALS pathogenesis.
- Analysis of molecular mechanisms including RNA foci and dipeptide repeat (DPR) formation.
- Examination of C9ORF72 protein function and its cellular roles.
Main Results:
- C9orf72 HRE causes toxic gain-of-function through RNA foci and DPRs, disrupting RNA processing, protein interactions, and cellular functions.
- HRE leads to loss of C9ORF72 function, impairing autophagy, increasing oxidative stress, and causing inflammation.
- Current therapeutic approaches targeting C9orf72 HRE have shown limited success.
Conclusions:
- C9orf72 HRE pathogenesis is complex, involving both toxic gain-of-function and loss-of-function.
- Further research into pharmacological and molecular modulators targeting C9orf72 HRE is necessary.
- Developing effective ALS therapies requires a deeper understanding and precise targeting of these genetic defects.
Related Concept Videos
In-vitro Mutagenesis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Reporter Genes
Gene Therapy
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

